PURPOSE: We speculated that a heterogeneous population of non-muscle invasive bladder cancer (NMIBC) patients with a previous history of smoking may be more precisely stratified by a biomarker associated with tumor aggressiveness and then focused on the preoperative neutrophil-to-lymphocyte ratio (pre-NLR), which is a simple index of systemic inflammation. METHODS: Our study population comprised 605 patients initially diagnosed with NMIBC at our 3 institutions between 1995 and 2013. We analyzed the relationships between pre-NLR levels and clinical outcomes in NMIBC. A pre-NLR level of ≥2.2 was defined as elevated according to a calculation by a receiver-operating curve analysis. RESULTS: In overall, a total of 296 patients (48.9 %) had pre-NLR ≥ 2.2, and the pre-NLR level was one of independent risk factors for tumor recurrence and stage progression. Among 344 patients with a previous history of smoking, 184 (53.5 %) had pre-NLR ≥ 2.2 and the pre-NLR level was one of independent risk factors for tumor recurrence and stage progression. The 5-year recurrence-free survival and progression-free survival rates in patients with pre-NLR < 2.2 were 66.3 and 97.5 %, respectively, which were significantly higher than those in their counterparts (31.7 and 90.4 %, p < 0.001). In either subgroup of patients who were current smokers (N = 175) or former smokers (N = 169), the pre-NLR level was the only independent risk factor for tumor recurrence. The pre-NLR level was not associated with tumor recurrence or stage progression in 261 nonsmoking patients. CONCLUSIONS: Pre-NLR levels may be a useful marker for identifying worse clinical outcomes in NMIBC patients, particularly those with a previous history of smoking.
PURPOSE: We speculated that a heterogeneous population of non-muscle invasive bladder cancer (NMIBC) patients with a previous history of smoking may be more precisely stratified by a biomarker associated with tumor aggressiveness and then focused on the preoperative neutrophil-to-lymphocyte ratio (pre-NLR), which is a simple index of systemic inflammation. METHODS: Our study population comprised 605 patients initially diagnosed with NMIBC at our 3 institutions between 1995 and 2013. We analyzed the relationships between pre-NLR levels and clinical outcomes in NMIBC. A pre-NLR level of ≥2.2 was defined as elevated according to a calculation by a receiver-operating curve analysis. RESULTS: In overall, a total of 296 patients (48.9 %) had pre-NLR ≥ 2.2, and the pre-NLR level was one of independent risk factors for tumor recurrence and stage progression. Among 344 patients with a previous history of smoking, 184 (53.5 %) had pre-NLR ≥ 2.2 and the pre-NLR level was one of independent risk factors for tumor recurrence and stage progression. The 5-year recurrence-free survival and progression-free survival rates in patients with pre-NLR < 2.2 were 66.3 and 97.5 %, respectively, which were significantly higher than those in their counterparts (31.7 and 90.4 %, p < 0.001). In either subgroup of patients who were current smokers (N = 175) or former smokers (N = 169), the pre-NLR level was the only independent risk factor for tumor recurrence. The pre-NLR level was not associated with tumor recurrence or stage progression in 261 nonsmoking patients. CONCLUSIONS: Pre-NLR levels may be a useful marker for identifying worse clinical outcomes in NMIBC patients, particularly those with a previous history of smoking.
Authors: Matteo Ferro; Marina Di Mauro; Sebastiano Cimino; Giuseppe Morgia; Giuseppe Lucarelli; Abdal Rahman Abu Farhan; Mihai Dorin Vartolomei; Angelo Porreca; Francesco Cantiello; Rocco Damiano; Gian Maria Busetto; Francesco Del Giudice; Rodolfo Hurle; Sisto Perdonà; Marco Borghesi; Pierluigi Bove; Riccardo Autorino; Nicolae Crisan; Michele Marchioni; Luigi Schips; Francesco Soria; Andrea Mari; Andrea Minervini; Alessandro Veccia; Michele Battaglia; Daniela Terracciano; Gennaro Musi; Giovanni Cordima; Matteo Muto; Vincenzo Mirone; Ottavio de Cobelli; Giorgio Ivan Russo Journal: Transl Androl Urol Date: 2021-02
Authors: Jiaguo Huang; Liwei Zhao; Kai Wang; Ji Sun; Shengcheng Tai; Runmiao Hua; Yufu Yu; Yi Fan Journal: Cancer Control Date: 2021 Jan-Dec Impact factor: 3.302
Authors: Ji-Qing Chen; Lucas A Salas; John K Wiencke; Devin C Koestler; Annette M Molinaro; Angeline S Andrew; John D Seigne; Margaret R Karagas; Karl T Kelsey; Brock C Christensen Journal: Clin Epigenetics Date: 2022-01-21 Impact factor: 6.551